A novel approach to 3-acylated indolizine structures via iodine-mediated hydrative cyclization

Tetrahedron Letters

Volumn 48, Issue 51, 2007, Pages 8976-8981

  Kim, Ikyon ^a   Kim, Sun Gi ^a   Kim, Ji Young ^a   Lee, Ge Hyeong ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

5 exo dig Iodocyclization; Hydrative cyclization; Indolizine; Iodine

Indexed keywords

2 PYRIDIN 2 YL PENT 4 YNOIC ACID ETHYL ESTER; 3 ACYLINDOLIZINE DERIVATIVE; 3 FORMYL INDOLIZINE 1 CARBOXYLIC ACID ETHYL ESTER; ALKYNE DERIVATIVE; INDOLIZINE DERIVATIVE; IODINE; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL REACTION; CHEMICAL STRUCTURE; CYCLIZATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SYNTHESIS;

EID: 36248968158     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2007.10.101     Document Type: Article

References (46)

1. Kim I., Lee G.H., and No Z.S. Bull. Korean Chem. Soc. 28 (2007) 685
2. Kim I., Choi J., Won H.K., and Lee G.H. Tetrahedron Lett. 48 (2007) 6863
3. Kim, I.; Won, H. K.; Choi, J.; Lee, G. H. Tetrahedron, in press. doi:10.1016/j.tet.2007.10.037.
4. For recent reviews on iodocyclizations, see:. Togo H., and Iida S. Synlett (2006) 2159
5. Martins da Silva F., Jones Jr. J., and de Mattos M.C.S. Curr. Org. Synth. 2 (2005) 393
6. For general reviews, see:. Shipman M. Sci. Synth. (2001) 745
7. Michael J.P. Nat. Prod. Rep. 17 (2000) 579
8. Grundon M.F. Nat. Prod. Rep. 6 (1989) 523
9. Flitsch W. In: Katritzky A.R., and Rees C.W. (Eds). Comprehensive Heterocyclic Chemistry Vol. 4 (1984), Pregamon Press, Oxford 443
10. Uchida T., and Matsumoto K. Synthesis (1976) 209
11. For recent examples on the synthesis of indolizines, see:. Schwier T., Sromek A.W., Yap D.M.L., Chernyak D., and Gevorgyan V. J. Am. Chem. Soc. 129 (2007) 9868
12. Seregin I.V., Schammel A.W., and Gevorgyan V. Org. Lett. 9 (2007) 3433
13. Chuprakov S., Hwang F.W., and Gevorgyan V. Angew. Chem., Int. Ed. 46 (2007) 4757
14. El Kaim L., Gizolme M., and Grimaud L. Synlett (2007) 227
15. Smith C.R., Bunnelle E.M., Rhodes A.J., and Sarpong R. Org. Lett. 9 (2007) 1169
16. Liu Y., Hu H.-Y., Liu Q.-J., Hu H.-W., and Xu J.-H. Tetrahedron 63 (2007) 2024
17. Marchalín S., Žúžiová J., Kadlečíková K., Šafář P., Baran P., Dalla V., and Daïch A. Tetrahedron Lett. 48 (2007) 697
18. Seregin I.V., and Gevorgyan V. J. Am. Chem. Soc. 128 (2006) 12050
19. Kaloko Jr. J., and Hayford A. Org. Lett. 7 (2005) 4305
20. Kel'in A.V., Sromek A.W., and Gevorgyan V. J. Am. Chem. Soc. 123 (2001) 2074
21. Padwa A., Austin D.J., Precedo L., and Zhi L. J. Org. Chem. 58 (1993) 1144
22. For selected examples on indolizine-based drug development, see:. Gundersen L.-L., Charnock C., Negussie A.H., Rise F., and Teklu S. Eur. J. Pharm. Sci. 30 (2007) 26
23. Hynd, G.; Ray, N. C.; Finch, H.; Montana, J. G.; Cramp, M. C.; Harrison, T. K.; Arienzo, R.; Blaney, P.; Griffon, Y.; Middlemiss, D. WO 2007031747 A1, 2007.
24. Millet R., Domarkas J., Rigo B., Goossens L., Goossens J.-F., Houssin R., and Henichart J.-P. Bioorg. Med. Chem. 10 (2002) 2905
25. Sonnet P., Dallemagne P., Guillon J., Enguehard C., Stiebing S., Tanguy J., Bureau R., Rault S., Auvray P., Moslemi S., Sourdaine P., and Seralini G.-E. Bioorg. Med. Chem. 8 (2000) 945
26. Hagishita S., Yamada M., Shirahase K., Okada T., Murakami Y., Ito Y., Matsuura T., Wada M., Kato T., Ueno M., Chikazawa Y., Yamada K., Ono T., Teshirogi I., and Ohtani M. J. Med. Chem. 39 (1996) 3636
27. Gubin J., de Vogelaer H., Inion H., Houben C., Lucchetti J., Mahaux J., Rosseels G., Peiren M., Clinet M., Polster P., and Chatelain P. J. Med. Chem. 36 (1993) 1425
28. Jaffrezou J.P., Levade T., Thurneyssen O., Chiron M., Bordier C., Attal M., Chatelain P., and Laurent G. Cancer Res. 52 (1992) 1352
29. Cingolani G.M., Claudi F., Massi M., and Venturi F. Eur. J. Med. Chem. 25 (1990) 709
30. For recent examples on 5-exo-dig iodocyclizations, see:. GowriSankar S., Lee M.J., Lee S., and Kim J.N. Bull. Korean Chem. Soc. 25 (2004) 1963
31. Wu Z., Minhas G.S., Wen D., Jiang H., Chen K., Zimniak P., and Zheng J. J. Med. Chem. 47 (2004) 3282
32. Hessian K.O., and Flynn B.L. Org. Lett. 5 (2003) 4377
33. Ren X.F., and Turos E. Tetrahedron Lett. 34 (1993) 1575
34. +: m/z 203.0949; found, 203.0947.
35. +: m/z 217.0739; found, 217.0742.
36. Transition-metal catalyzed hydrative cyclization is well known. For recent examples, see:. Chang H.-K., Datta S., Das A., Odedra A., and Liu R.-S. Angew. Chem., Int. Ed. 46 (2007) 4744
37. Trost B.M., and Huang X. Chem.-Asian J. 1 (2006) 469
38. Matsuda T., Kadowaki S., and Murakami M. Helv. Chim. Acta 89 (2006) 1672
39. Chen Y., Ho D.M., and Lee C.B. J. Am. Chem. Soc. 127 (2005) 12184
40. Trost B.M., and Rudd M.T. J. Am. Chem. Soc. 127 (2005) 4763
41. Iodine-promoted hydrative cyclization was exploited by Flynn and co-workers in their approach to variously substituted benzothiophenes but with a little different mechanism. See Ref. 6c.
42. For the use of hypervalent iodine reagents such as PIFA in hydrative cyclizations, see:. Tellitu I., Serna S., Herrero M.T., Moreno I., Dominguez E., and SanMartin R. J. Org. Chem. 72 (2007) 1526 and references cited therein
43. Structurally relevant indolizine oxalylamides (for example, STA-5312) are known to exhibit microtubule inhibitory effect. Li H., Xia Z., Chen S., Koya K., Ono M., and Sun L. Org. Process Res. Dev. 11 (2007) 246.{A figure is presented}
44. Przewloka T., Chen S., Xia Z., Li H., Zhang S., Chimmanamada D., Kostik E., James D., Koya K., and Sun L. Tetrahedron Lett. 48 (2007) 5739
45. 4 was prepared by following the procedure of Lee. See:. Lee P.H., Kim H., and Lee K. Adv. Synth. Catal. 347 (2005) 1219
46. In case of 4, small amount of 5′ was also isolated.{A figure is presented}